Company Overview of AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP, a biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription medicines to customers worldwide. It offers medicines primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases. The company was founded in 1912 and is headquartered in Wilmington, Delaware. It has research and development, manufacturing, and commercial office locations in California, Delaware, Kentucky, Massachusetts, Maryland, North Carolina, Ohio, and Pennsylvania. AstraZeneca Pharmaceuticals LP operates as a subsidiary of AstraZeneca PLC.
1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437
Founded in 1912
Key Executives for AstraZeneca Pharmaceuticals LP
Chief Financial Officer and Vice President of Finance - North America
Executive Vice President of North America and President of Astrazeneca US
President of Astrazeneca Canada Inc
Vice President of Medical Affairs and US Head Medical Officer
Chief Operating Officer of U.S. Business
Compensation as of Fiscal Year 2016.
AstraZeneca Pharmaceuticals LP Key Developments
AstraZeneca Pharmaceuticals LP Wins $345.95 Million Federal Contract
Jul 12 16
AstraZeneca Pharmaceuticals LP won a $345,952,920 federal contract from the Department of Veterans Affairs' National Acquisition Center for inhalers.
Cerulean Pharma Inc. Enters into Lease Agreement with Astrazeneca Pharmaceuticals Limited Partnership
Jul 14 15
On July 9, 2015, Cerulean Pharma Inc. (the Company) entered into a lease agreement (the Lease) with AstraZeneca Pharmaceuticals Limited Partnership, a Delaware limited partnership (the Landlord), for approximately 22,992 square feet of laboratory and office space at 35 Gatehouse Drive in Waltham, Massachusetts. The term of the Lease commences on December 28, 2015 and expires on February 28, 2021. During each of the first two years of the term, the Company's annual base rent will be $689,760. The annual base rent shall increase each year thereafter. In addition to the base rent, the Company is also responsible for its share of the operating expenses, utility costs and real estate taxes, in accordance with the terms of the Lease. Pursuant to the terms of the Lease, the Company is required to provide a security deposit in the form of a letter of credit in the amount of $229,920. The Company has the right to extend the term of the Lease for one three-year term, provided that the Company provides notice to the Landlord not later than 12 months prior to the expiration date of the initial term. The base rent for the extension term, if any, will be determined based on market conditions existing at such time in accordance with the terms of the Lease. The Lease contains customary provisions allowing the Landlord to terminate the Lease if the Company fails to remedy a default of any of its obligations under the Lease within specified periods or upon the bankruptcy or insolvency of the Company.
Faruqi & Faruqi, LLP and Berger & Montague,P.C. Reach Whistleblower Lawsuit Settlement with AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc
Jul 7 15
Faruqi & Faruqi, LLP and co-counsel Berger & Montague,P.C. announced that they have reached a settlement in three separate but related whistleblower lawsuits alleging violations of the False Claims Act against AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc., for a total of $55.5 million. The cases were jointly prosecuted by Faruqi & Faruqi, LLP and Berger & Montague, P.C. on behalf of Relator Ronald J. Streck, who filed this action in 2008. Under the terms of the settlement, AstraZeneca will pay $46.5 million, Cephalon will pay $7.5 million, and Biogen will pay $1.5 million. Claims against a fourth drug manufacturer, Genzyme Corporation, are still being litigated. The case, pending in federal court in the Eastern District of Pennsylvania, is captioned United States ex rel. Ronald Streck versus Allergan, et al., Case No. 08-cv-5135. The lawsuit, filed on behalf of the United States under the False Claims Act (FCA) and State False Claims Acts alleges that a number of pharmaceutical manufacturers, including AstraZeneca, Cephalon and Biogen, fraudulently underpaid mandatory rebates to state Medicaid programs. Streck's lead attorney, T. Talyana Bromberg of Faruqi & Faruqi, LLP, stated: "When pharmaceutical companies manipulate prices in order to underpay Medicaid, every taxpayer suffers.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|